The effect of sleep apnea on all-cause mortality in nondialyzed chronic kidney disease patients

Xu, Juan; Yoon, Il; Chin, Ho Jun

doi:10.1016/j.sleep.2016.07.026

Cited by 26 publications

(16 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The relationship between sleep apnea and kidney impair/disease is confirmed by several previous studies [3–5, 17–20]. A population-based cohort study in Taiwan demonstrated that patients with sleep apnea had a 1.94-fold and 2.2-fold increase in the incidences of chronic kidney disease and end-stage renal disease [18].…”

Section: Discussionsupporting

confidence: 63%

Telmisartan attenuates kidney apoptosis and autophagy-related protein expression levels in an intermittent hypoxia mouse model

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 63%

Telmisartan attenuates kidney apoptosis and autophagy-related protein expression levels in an intermittent hypoxia mouse model

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Three studies were from China and Hong Kong China . The rest 6 studies were from Italy, Switzerland, German, the UK, South Korea and Greece, respectively . Nearly half of these studies assessed the prevalence of SA by sleep‐related questionnaires as well, such as ESS, PSQI and STOP‐Bang questionnaire (Table ).…”

Section: Resultsmentioning

confidence: 99%

Prevalence of sleep apnoea in non‐dialysis chronic kidney disease patients: A systematic review and meta‐analysis

et al. 2019

View full text Add to dashboard Cite

This is a meta-analysis evaluating the prevalence of sleep apnoea (SA) in patients with chronic kidney disease (CKD). The authors found that SA is commonly seen in both early and advanced nondialysis CKD patients, and the prevalence of SA increases in advanced CKD. And male patients are more likely to be affected by SA than female patients. ABSTRACT:Aim: The prevalence of sleep apnoea (SA) in chronic kidney disease (CKD) varies greatly across preceding studies. The aim of our study was to provide a summary of the prevalence of SA among non-dialysis CKD patients. Method: Medline, Embase, Web of Science, China Knowledge ResourceIntegrated Database, VIP Chinese scientific journal database (VIP) and Wanfang Digital Periodical Full-text database were searched up to September 2018 to identify publications related to the prevalence of SA in non-dialysis CKD patients assessed by sleep questionnaires or sleep respiration monitoring. Random-effects meta-analysis was used to estimate pooled prevalence of SA. And subgroup analysis and meta-regression were conducted as well.Results: The pooled prevalence of SA in the included 26 studies was 38% (95% confidence interval [CI], 21-70%). In subgroup analyses, the pooled prevalence of SA varied using different diagnostic tools. The pooled prevalence of questionnaire-based SA for CKD was 10% (95% CI, 3-27%), while the prevalence of sleep monitoring-based SA was 56% (95% CI, 49-66%). Also, advanced CKD patients had a greater chance to suffer from moderate-to-severe SA than early stage CKD patients. Male patients were more likely to be affected by moderate-to-severe SA than female patients (47% vs 30%, P = 0.018).

show abstract

“…The prevalence of CSA in patients with CKD might be as high as 2.9 times after adjustment for modifiable risk factors such as age, sex, and obesity. 50 CSA was found to be an independent risk factor for all-cause mortality, and SDB conferred greater risk of mortality in patients with CKD compared to patients without CKD. 50 CSA may contribute to rapid worsening of renal function in patients with CKD, which might be one of the major reasons for the increase in all-cause mortality.…”

Section: Introductionmentioning

confidence: 91%

“… 50 CSA was found to be an independent risk factor for all-cause mortality, and SDB conferred greater risk of mortality in patients with CKD compared to patients without CKD. 50 CSA may contribute to rapid worsening of renal function in patients with CKD, which might be one of the major reasons for the increase in all-cause mortality. Nocturnal HD and renal transplantation appear to be reasonable treatment options for treatment of CSA in patients with CKD depending on disease severity and patient acceptability.…”

Section: Introductionmentioning

confidence: 91%

Exploring sleep disorders in patients with chronic kidney disease

Nigam

Camacho

Chang

et al. 2018

NSS

View full text Add to dashboard Cite

Kidney disorders have been associated with a variety of sleep-related disorders. Therefore, researchers are placing greater emphasis on finding the role of chronic kidney disease (CKD) in the development of obstructive sleep apnea and restless legs syndrome. Unfortunately, the presence of other sleep-related disorders with CKDs and non-CKDs has not been investigated with the same clinical rigor. Recent studies have revealed that myriad of sleep disorders are associated with CKDs. Furthermore, there are a few non-CKD-related disorders that are associated with sleep disorders. In this narrative review, we provide a balanced view of the spectrum of sleep disorders (as identified in International Classification of Sleep disorders-3) related to different types of renal disorders prominently including but not exclusively limited to CKD.

show abstract

The effect of sleep apnea on all-cause mortality in nondialyzed chronic kidney disease patients

Cited by 26 publications

References 25 publications

Telmisartan attenuates kidney apoptosis and autophagy-related protein expression levels in an intermittent hypoxia mouse model

Telmisartan attenuates kidney apoptosis and autophagy-related protein expression levels in an intermittent hypoxia mouse model

Prevalence of sleep apnoea in non‐dialysis chronic kidney disease patients: A systematic review and meta‐analysis

Exploring sleep disorders in patients with chronic kidney disease

Contact Info

Product

Resources

About